# Treatment Satisfaction With Ra-223 in Japan

> **NCT03315260** · — · COMPLETED · sponsor: **Bayer** · enrollment: 85 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT03315260
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-11
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-03-20
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2024-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315260, "Treatment Satisfaction With Ra-223 in Japan". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03315260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*